Zepbound has doubled its market share in a year, nearly matching Wegovy at around two in five weight loss prescriptions, DRG Fingertip data shows.<\/p>\n
Since July 1, 2025, CVS Caremark has continued to prefer Wegovy on its national formularies while removing Zepbound, which resulted in its formulary coverage dropping 17 points to 83% in a month. For plan formularies administered by CVS Caremark, Wegovy is being increasingly covered, although as a non-preferred restricted drug.<\/p>\n
Beyond formulary inclusion, insurers are increasingly relying on utilization management tools. While CVS Caremark has expanded Wegovy coverage, prior authorization requirements have also intensified. Insurers are offering opt-in or limited coverage options for GLP-1s and adding weight and lifestyle management programs or enticing clients with cost guarantees.<\/p>\n
Patients are increasingly willing to bypass insurance for weight loss solutions, or seeking holistic and lifestyle-based interventions. A growing number of telemedicine vendors are entering the space, offering convenience and accessibility to patients who can afford to forego coverage.<\/p>\n
For manufacturers, scaling up production to meet demand and negotiating with insurers to improve coverage terms is critical. Enhancing patient satisfaction and prescribing confidence can boost sales through direct-to-consumer strategies.<\/p>\n
Along with aggressive formulary selection, payers will utilize hybrid models combining drug coverage with lifestyle programs and cost guarantees.<\/p>\n
Telehealth providers can benefit from leveraging GLP-1 demand to expand service offerings and partnerships, while employer wellness platforms offer an opportunity to integrate weight loss solutions into benefits packages.<\/p>\n
DRG Fingertip\u2019s suite of solutions delivers pharmacist-validated, AI-powered visibility into the industry\u2019s most accurate market access intelligence, including coverage, restrictions, source transparency and policy change tracking.<\/p>\n